, Volume 175, Issue 3, pp 367–373

Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients

  • Rodrigo A. Bressan
  • Kjell Erlandsson
  • Edgar P. Spencer
  • Peter J. Ell
  • Lyn S. Pilowsky
Original Investigation



Atypical antipsychotic drugs are classically associated with lower propensity to extrapyramidal symptoms (EPS) and hyperprolactinemia than typical antipsychotic drugs. It has not been clarified why some atypical antipsychotic drugs, such as amisulpride, induce prolactin plasma concentration (PRL) elevation, but little EPS. Previous studies have found an association between striatal D2/D3 receptor occupancy and PRL in typical antipsychotic treated patients suggesting that PRL is a marker of central D2/D3 receptors blockade.


We have evaluated the relationship between PRL and central (striatum, temporal cortex and thalamus) D2/D3 receptor occupancy in amisulpride treated schizophrenic patients.


Single photon emission tomography (SPET) and [123I]-epidepride were used to determine D2/D3 receptor occupancy in eight amisulpride treated patients. PRL was measured concurrently with the scans.


The mean PRL was 1166 (range 499–1892 mIU/l) for a mean amisulpride dose of 406 mg/day (range 150–600 mg/day). Amisulpride plasma concentration and central D2/D3 receptor occupancy were positively correlated (r=0.83–0.89, df=4, P<0.05). No significant correlations were observed between PRL and amisulpride (daily dose or plasma concentration, P>0.05), or between PRL and central D2/D3 receptor occupancy (P>0.05).


Our findings show that amisulpride-induced hyperprolactinemia is uncoupled from central D2/D3 receptor occupancy. Amisulpride has poor blood–brain barrier penetration and reaches much higher concentration at the pituitary, which is outside the blood–brain barrier. Higher D2/D3 receptor occupancy at the pituitary gland than at central regions is a possible explanation for amisulpride PRL elevation with low EPS. Further studies evaluating pituitary D2/D3 receptor occupancy in vivo are necessary to confirm this hypothesis.


Prolactin Antipsychotic agents Atypical antipsychotic Neuroleptic Dopamine receptor D2-dopamine Schizophrenia SPECT [123I]-epidepride Amisulpride Photon emission tomography 


  1. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201–208CrossRefGoogle Scholar
  2. Alcohol Drug Abuse, and Mental Health Administration (1974) Abnormal involuntary movement scale (AIMS). Department of Health, Education and Welfare, Washington D.C.Google Scholar
  3. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676PubMedGoogle Scholar
  4. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS (2003a) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413–1420CrossRefPubMedGoogle Scholar
  5. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003b) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23:5–14CrossRefPubMedGoogle Scholar
  6. Brown WA, Laughren TP (1981) Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res 5:317–322CrossRefPubMedGoogle Scholar
  7. Erlandsson K, Bressan RA, Mulligan RS, Ell PJ, Cunningham VJ, Pilowsky LS (2003) Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings. Neuroimage 19:1205–1214CrossRefPubMedGoogle Scholar
  8. Flores CM, Hulihan-Giblin BA, Hornby PJ, Lumpkin MD, Kellar KJ (1992) Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology 55:519–528PubMedGoogle Scholar
  9. Folstein M, Folstein F, McHugh P (1975) Mini mental state—a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12:189–198PubMedGoogle Scholar
  10. Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, Halpern FS (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35:108–116PubMedGoogle Scholar
  11. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, Hiemke C, Benkert O (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45:89–97PubMedGoogle Scholar
  12. Igarashi Y, Higuchi T, Toyoshima R, Noguchi T, Moroji T (1985) Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol 40:95–98PubMedGoogle Scholar
  13. Invitti C, Danesi L, Dubini A, Cavagnini F (1998) Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients. Acta Endocrinol 118:381–388Google Scholar
  14. Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacology 35:1503–1519Google Scholar
  15. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520PubMedGoogle Scholar
  16. Kapur S, Langlois X, Vinken P, Megens AA, de Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129–1134CrossRefPubMedGoogle Scholar
  17. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276Google Scholar
  18. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19:603–606PubMedGoogle Scholar
  19. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158CrossRefPubMedGoogle Scholar
  20. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RSJ (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16:42–52PubMedGoogle Scholar
  21. Laughren TP, Brown WA, Williams BW (1979) Serum prolactin and clinical state during neuroleptic treatment and withdrawal. Am J Psychiatry 136:108–110PubMedGoogle Scholar
  22. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180–190CrossRefPubMedGoogle Scholar
  23. Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc’h C, Maziere B (1996) In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124:154–158PubMedGoogle Scholar
  24. Melkersson KI, Hulting AL, Rane AJ (2001) Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51:317–324CrossRefPubMedGoogle Scholar
  25. Meltzer HY (1985) Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol 40:59–68PubMedGoogle Scholar
  26. Meltzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33:279–286PubMedGoogle Scholar
  27. Mizuchi A, Kitagawa N, Miyachi Y (1983) Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology 81:195–198PubMedGoogle Scholar
  28. Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L (1998) Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 96:223–226Google Scholar
  29. Naber D, Fischer H, Ackenheil M (1979) Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance? Commun Psychopharmacol 3:59–65PubMedGoogle Scholar
  30. Nördstrom AL, Farde L (1998) Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 18:305–310PubMedGoogle Scholar
  31. Nördstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227–235PubMedGoogle Scholar
  32. Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812Google Scholar
  33. Protais P, Hermier C, Costentin J (1985) The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration. Neuropharmacology 24:861–867CrossRefPubMedGoogle Scholar
  34. Rao ML, Brown WA (1987) Stability of serum neuroleptic and prolactin concentrations during short-term and long-term treatment of schizophrenic patients. Psychopharmacology 93:237–242Google Scholar
  35. Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273–282Google Scholar
  36. Schlosser R, Grunder G, Anghelescu I, Hillert A, Ewald-Grunder S, Hiemke C et al. (2002) Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 46:33–40CrossRefPubMedGoogle Scholar
  37. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19Google Scholar
  38. Talairach J, Tourneaux P (1988) Co-planar stereotactic atlas of the human brain. Thieme, New YorkGoogle Scholar
  39. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc’h C, Maziere B, Paillere-Martinot ML (2001) In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21:207–214CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Rodrigo A. Bressan
    • 1
    • 2
  • Kjell Erlandsson
    • 3
  • Edgar P. Spencer
    • 4
  • Peter J. Ell
    • 3
  • Lyn S. Pilowsky
    • 1
    • 3
  1. 1.Section of Neurochemical Imaging, Institute of PsychiatryKing’s College LondonLondonUK
  2. 2.Departamento de PsiquiatriaUniversidade Federal de Sao Paulo-UNIFESPSao Paulo, SPBrazil
  3. 3.Institute of Nuclear Medicine, Middlesex HospitalUCL Medical SchoolLondonUK
  4. 4.Medical Toxicology UnitGuy’s and St Thomas’ Hospital TrustLondonUK

Personalised recommendations